Outset Medical to Present Research Highlighting Home Hemodialysis Success for Underserved Populations at National Kidney Foundation Spring Clinical Meetings
Abstracts include results of innovative home hemodialysis program in
“Kidney disease is debilitating and takes away the freedom of choice for patients,” said
The research will be presented at the
“Our latest studies demonstrate how Outset is working to bring innovation to the dialysis industry by overcoming the bias that chronic kidney disease (CKD) patients need perfect conditions to treat at home,” said
The following abstracts will be presented at the NKF SCM23:
Redefining Dialysis Care on the Hawaiian Islands: Reducing Health Disparities and Resource Utilization — An HHD program implemented on the islands of
The Transition from Peritoneal Dialysis (PD) to Home Hemodialysis at Hospital Discharge — This case study focuses on the successful transition from PD to HHD using Tablo and how it can be done successfully. Once patients are performing dialysis at home, they can continue treating at home, even if they initially began dialysis in a hospital urgent-start setting.
Gender Biases in Nephrology: A 2022 Survey of Female Nephrologists — Survey results show that women in nephrology believe much more is needed to close the existing gender gap that prevents women from reaching leadership roles and equitable pay. Those surveyed weighed in on the need for female mentors, a better cultural environment in the workplace and improved work-life integration. Only 6.7% of respondents were confident that change would happen, so broader initiatives are required.
Home Hemodialysis Can Help Reduce Total Cost of Care among Medicare Advantage Members with ESRD — HHD use is increasing in the
Home Hemodialysis Can Help Providers Reduce Total Cost of Care in Risk-Based Contracts with Medicare Advantage (MA) Organizations — Modeled analysis showing costs for a dialysis population from a MA health plan and the five-year savings generated by establishing a home dialysis program. Using parameters of 500 MA dialysis members, analysis shows estimated total savings of
The abstracts can be read in their entirety on the
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s beliefs, projections and expectations concerning, among other things, the potential impact of the research results discussed in this press release. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset’s public filings with the
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA-cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of
Vice President, Investor Relations for